Mesenteric CD103<sup>+</sup>DCs Initiate Switched Coxsackievirus B3 VP1-Specific IgA Response to Intranasal Chitosan-DNA Vaccine Through Secreting BAFF/IL-6 and Promoting Th17/Tfh Differentiation

Haoxin Zhao, Jie Yang, Qian Qian, Manli Wu, Min Li and Wei Xu*

Jiangsu Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Sciences, Soochow University, Suzhou, China

Intranasal chitosan-formulated DNA vaccination promotes IgA secretion in the intestine. However, the mechanism whereby chitosan-DNA skews IgA class switch recombination (CSR) of B cells in the Gut-associated lymph tissue (GALT) is not fully resolved. In this study, we investigated the effects of nasally administered chitosan-DNA (pcDNA3.1-VP1 plasmid encoding VP1 capsid protein of Coxsackievirus B3) on IgA production, DC activation and Tfh/Th17 response in the intestine. Compared to DNA immunization, intranasal chitosan-DNA vaccination induced antigen-specific IgA production in feces, a pronounced switching of antigen-specific IgA plasmablast B cells in the mesenteric lymph nodes (MLNs) and an enhanced expression of post-recombination I<sub>α</sub>-CH transcripts/IgA germline transcript (αGT) as well as activation-induced cytidine deaminase (AID) in MLN B cells. MLN Tfh frequency was markedly enhanced by chitosan-DNA, and was associated with VP1-specific IgA titer. 24 h after immunization, intranasal chitosan-DNA induced a recruitment of CD103<sup>+</sup>DCs into the MLN that paralleled a selective loss of CD103<sup>+</sup>DCs in the lamina propria (LP). In vivo activated MLN-derived CD103<sup>+</sup>DCs produced high levels of IL-6 and BAFF in response to chitosan-DNA, which up-regulated transmembrane activator and CAML interactor (TACI) expression on MLN B cells. Upon co-culture with IgM<sup>+</sup>B in the presence of chitosan-DNA, MLN CD103<sup>+</sup>DCs induced IgA production in a T-dependent manner; and this IgA-promoting effect of CD103<sup>+</sup>DC was blocked by targeting TACI and, to a lower extent, by blocking IL-6. MLN CD103<sup>+</sup>DCs displayed an enhanced capacity to induce an enhanced CD4<sup>+</sup>Th17 response in vivo and in vitro, and IL-17A deficient mice had a pronounced reduction of specific intestinal IgA following immunization. Taken together, mesenteric CD103<sup>+</sup>DCs are indispensable for the adjuvant activity of chitosan in enhancing DNA vaccine-specific IgA switching in gut through activating BAFF-TACI and IL-6-IL-6R signaling, and through inducing Th17/Tfh differentiation in the MLN.

Keywords: IgA, class switch recombination (CSR), chitosan, CD103<sup>+</sup> DC, TACI
INTRODUCTION

The predominant immunoglobulin at the mucosal surfaces is secretory IgA (SlgA) serving as the first defense against pathogens through immune exclusion. It also plays important roles in establishing a healthy microbiota and maintaining mucosal homeostasis (1, 2). Impaired IgA production is associated with recurrent respiratory and gastrointestinal infections as well as allergy seen in patients with common variable immunodeficiency (CVID) and hyper-IgM (HIGM) syndrome (3). Polymeric immunoglobulin receptor (pIgR) deficient mice which lack SlgA, lose their protection against cholera toxin (CT) after oral immunization with Salmonella typhimurium (4). Passive transfer of IgA and IgA depletion assays demonstrate the protective role of mucosal SlgA against influenza virus and Sendai virus infection (5). SlgA could neutralize intracellular pathogens. Mucosal application of anti-human immunodeficiency virus (HIV) envelope dimeric IgA1 provides potent protection against mucosal transmission of HIV-1 (6). An insufficient induction of effector T cells and SlgA in the lung at the time of Mycobacterium tuberculosis (M.tb) infection is also suggested as one of the limitations of BCG vaccine (7). In this regard, mucosal immunization with vaccine antigens, or mucosal passive application of pathogen-specific SlgAs at the mucosa where is the initial entry site for most infectious agents, can be effective alternatives to achieve mucosal protection against severe mucus-related infectious disease (8).

IgA generation is potentiated by class switch recombination (CSR) of the B cells (9). CSR is induced by both T cell-dependent (TD) and -independent (ITI) pathways. High-affinity IgA emerges from follicular B cells in Peyer’s patches (PP) and mesenteric lymph nodes (MLN) after recognizing microbial toxins and pathogens via TD pathways, whereas intestinal commensals stimulate extra-follicular B cells to generate low-affinity IgA via ITI pathways (10). In the TD pathway, CD40 signaling from CD4+ Th cells is critical for generation of germinal centers (GCs) and induction of activation-induced cytidine deaminase (AID), an essential DNA-editing enzyme directing CSR of B cells, in GC B cells (11). DCs are key contributors to induction and regulation of IgA CSR and differentiation of B cells into IgA plasma cells (PCs) in the intestine mucosa. Upon sampling antigen directly or from M cells, DCs migrate to PP or to the draining MLN to establish cognate interactions with CD4+ T cells, inducing Th2, regulatory T cell (Treg), and T follicular helper (Tfh) cells that activate follicular B cells and initiate IgA responses via CD40L and cytokines (TGF-β, IL-4, IL-10, and IL-21) (12). Meanwhile, various DC subsets release TGF-β, IL-10, retinoic acid (RA), nitric oxide (NO), activating factor of the TNF family (BAFF) and a proliferation-inducing ligand (APRIL) by TLRs stimulation which activate B cells by binding with receptors on B cells such as BAFF-R, B cell maturation antigen (BCMA) or transmembrane activator and CAML receptor (TACI) (13, 14).

CD103+ DCs are the most abundant intestinal DC subset (15). Gut CD103+ DCs comprise two major subsets, CD103+CD11b+ cDCs and CD103+CD11b- cDCs. CD103+CD11b+ DCs are the major subsets in the SI-lamina propria (LP) and the major migratory DC subset (16). They present oral antigens and induce the differentiation of T cells into CD4+ Foxp3+Th3 type via generating TGF-β and RA (17), while CD103+CD11b- DCs are the dominant population in the PPs and colon LP. Both human CD103+ DC subsets induce Th17 polarization (18) while murine CD103+CD11b+ DCs support Th17 differentiation in the MLN by producing IL-6 (19). CD103+DCs-mediated enhancement of local Treg differentiation is associated with a pronounced switching of specific B cells to IgA in the MLN (20). Also, antigen-specific Th17 response is associated with enhanced neutralizing mucosal IgA exclusively after mucosal immunization (21). Although studies have assessed the function of intestinal CD103+DCs in vitro, their roles in intestinal adaptive immune responses in vivo and their involvement in the IgA CSR of intestinal B cells to vaccine antigens and adjuvants are not fully clarified.

In our previous work, formulation DNA (pcDNA3.1-VP1 plasmid encoding VP1 capsid protein of Coxsackievirus B3) vaccine with chitosan, a natural cationic polysaccharide deacetylated from chitin, efficiently promotes the protection against CVB3 infection via eliciting considerable enhanced IgA and T response at the intestine (22–24). Chitosan has been widely used as mucosal carrier for vaccines and as ideal adjuvant (25). Regarding its mucosal IgA-enhancing mechanism, some researchers attribute it to the macrophage-modulatory effect of chitosan (26). Recent studies indicate that chitosan engages the cGAS-STING pathway to trigger antigen specific Th1 and IgG2c responses following chitosan-protein vaccination (27). A combination of chitosan with CpG, TLR9 agonist, induces NLRP3-dependent antigen-specific Th1 and Th17 responses (28). Chitosan substrate culture of DCs up-regulates CD80/86 expression on DC and enhances IL-12 secretion by DCs which promotes the induction of anti-tumor IFNγ+ CTL activity in mice (29). Chitosan-DNA nanoparticles, prepared by co-precipitation of chitosan and DNA, are known to elevate mucosal SlgA induction (30) by stimulating maturation and function of DC (31, 32). Nevertheless, how chitosan-formulated DNA engages intestinal DC subsets to activate specific intestinal B cells which undergo class switching to SlgA remains largely unexplored.

In the present study, to elucidate cellular and molecular mechanisms underlying the effects of chitosan-DNA on intestinal DCs and antigen-specific IgA production, mice were intranasally (i.n.) immunized with chitosan-DNA and the targeted DC subsets and IgA-producing B response in the intestine were studied. We show that i.n. immunization with chitosan-DNA induces an enhanced recruitment of CD103+DCs into the MLNs, which markedly increases the differentiation of GC Tfh cells, Ag-specific IgA+ plasmablast and plasma cells. CD4+Th17 response is preferentially induced by chitosan-DNA in vivo and in vitro,

Abbreviations: αGT, α-germline transcript; AID, Activation-induced cytidine deaminase; APRIL, a proliferation-inducing ligand; BAFF, B cell activating factor of the TNF family; BAFF-R, BAFF receptor; BCMA, B cell maturation antigen; cDC, classical DC; CVB3, Coxsackievirus B3; CSR, Class switch recombination; GALT, Gut-associated lymph tissue; GC, Germinal center; LP, Lamina propria; mDC, migratory DC; MLN, Mesenteric lymph node; PC, Plasma cells; PP, Peyer’s patch; rDC, resident DC; TACI, Transmembrane activator and CAML receptor; Tfh, T follicular helper; VP1, Viral protein 1.
which is required for the Ag-specific IgA production in the intestine.

**MATERIALS AND METHODS**

**Mice and Peptide**

Six to eight weeks old male BALB/c mice were obtained from Slac Laboratory Animal (Shanghai, China) and housed under pathogen-free conditions at the Soochow University Laboratory Animal Center. IL-17A knockout mice were a gift from Prof Chen Dong (Tsinghua University, China). Animal experiments were performed in accordance with the Institutional Animal Care and Use Committee of Soochow University. All research protocols were approved by the Animal Ethical Committee of Soochow University (SYXX2015-0058). CVB3 VP1237–249 Peptide (FKPKHVKAWIPRP) was synthesized by GL Biochem Corp (Shanghai, China) with purity over 95%.

**Intranasal Chitosan-DNA Immunization**

Chitosan-DNA(pcDNA3.1-VP1) complex was prepared as described previously (22, 23). Equal volumes of chitosan solution (Fluka BioChemika, 0.02%, w/v in 5 mM NaAc-HAc buffer, pH 5.5) and DNA solution (400 µg/ml in 5 mM Na2SO4) were heated to 55°C and then vigorously mixed for 30 s. After anesthetization with 0.75% pentobarbital sodium, mice were intranasally immunized with chitosan-DNA (50 µg), DNA, chitosan or PBS. This procedure was conducted on day 0, 14, 28, and 42. Fecal extracts were prepared by mashing feces pellets in PBS containing a protease inhibitor cocktail (5% non-fat milk, 1 µg/ml aprotinin, 1 mM PMSF) at final concentration of 100 mg/ml before centrifuging at 12,000 rpm for 10 min. Supernatants were collected and stored at −80°C for further analysis.

**ELISPOT Analysis**

The filtration plate (Millipore) was coated overnight at 4°C with 10 µg/ml VP1237–249 peptide. After washing, the plate was blocked with complete RPMI-1640 for 2 h. Splenocytes or GALT lymphocytes were applied (5 × 10^6/well) and incubated for 6 h at 37°C with LPS (100 ng/ml, Sigma-Aldrich) as positive control. After removing the supernatant, ice-cold deionized water was added and incubated on ice for 10 min to lyse the remaining cells. After washing, alkaline phosphatase-conjugated goat anti-mouse IgA (Southern Biotech) was added and incubated overnight. The enzyme activity was revealed by using Sigma Fast BCIP/NBT (Sigma-Aldrich). Spots were counted using ImmunoSpot analyzer 5.1.36 software (Cellular Technology).

**IgA and Cytokine Measurements**

Total IgA levels were assessed using an ELISA kit (Bethyl Laboratory, United States) according to the manufacturer’s instructions. VP1-specific IgA levels were evaluated using an ELISA in accordance with previously published methods (33). Instead of the primary antibody in the mouse IgA ELISA kit, VP1237–249 peptide was suspended in 0.05 M carbonate-bicarbonate buffer (pH 9.6) and coated the ELISA plate at 10 µg/ml. Subsequently, the kit was used according to the manufacturer’s instructions. Mouse IL-17A, IL-6, IL-12p40, IL-12p70, IL-23p19, and IFNγ in the culture supernatants were quantified using ELISA kits (R&D Systems, MN, United States) in accordance with the manufacturer’s instructions. Mouse BAFF was quantified by ELISA kit (Abcam, Cambridge, United Kingdom).

**Isolation of Tissue Lymphocytes**

Single-cell suspensions of spleen lymphocytes were obtained by gently pressing the spleen against a 70-µm strainer and then removing erythrocytes by brief exposure to 0.16 M NH4Cl at room temperature for 3 min. PP and MLN lymphocytes were prepared as previously reported, with some modifications (34). Both PP and MLN cells were digested with collagenase Type IV (0.5 mg/ml, Sigma-Aldrich) and DNase I (5 µg/ml, Sigma-Aldrich) for 30 min and made into single-cell suspensions. For isolation of PP lymphocytes, small intestines were removed after excluding PPs and then cut into 1-cm pieces and opened up. They were minced in Mg2+/Ca2+-free HBSS supplemented with 2% FBS, and then 2.5 mM EDTA to remove mucus and epithelial cells at 37°C for 30 min. Tissues were then digested with RPMI 1,640–5% FBS with 1 mg/mL collagenase IV and 5 µg/ml DNase I for 45 min at 37°C under gentle shaking. After filtering through a 70-µm mesh the PP lymphocytes were isolated at the 40–70% interface of a discontinuous Percoll (GE Healthcare, UK) gradient and resuspended in RPMI 1640 medium after centrifugation at 800× g for 20 min.

**Induction of IgA Production by DC-B-Th Cell Co-culture**

BALB/c mice were immunized with chitosan-DNA (50 µg, i.n.) for 24 h. MLN single-cell suspension were prepared as described earlier. MLN CD11c+MHCII+DCs were sorted on the basis of their expression of CD103 using a FACSArria (BD Biosciences) (>95% purity). Naïve MLN B cells were sorted on the basis of their expression of IgM and CD19 using a FACSArria. Naïve CD4+CD62L*high T cells from MLN of mice were prepared using MACS beads (Miltenyi Biotec, Germany). For in vitro IgA switching, naïve B cells (5 × 10^5) were co-cultured with naïve CD4+Th0 cells (5 × 10^5) and with MLN CD103+ DCs (2.5 × 10^4) in the presence of DNA or chitosan-DNA (5 µg/ml) for 4 days after which VP1237–249 peptide was added for another 3 days. Neutralizing Ab against IL-6 (10 µg/ml, BD Pharmingen), TACI (5 µg/ml, R&D system) or rat IgG1 isotype control (10 µg/ml, BD Pharmingen) was added to cultures. VP1-specific IgA in the culture supernatants was quantified by ELISA.

**Flow Cytometric Analysis**

Flow cytometry Abs were purchased from BD Pharmingen, e-Bioscience and Biolegend (San Diego, CA). Single-cell suspensions, after anti-CD16/CD32 blocking, were stained for 25 min at 4°C with the following primary Abs or isotype controls: IgA-FITC (Clone C10-3), B220-PE (Clone RA3-6B2), CD138-APC (clone 281-2), CD5-PE (clone 53-7.3), CXCXR5-PE-Cy7 (clone L138D7), PD1-FITC (clone J43), CD11b-APC (Clone M1/70), CD86-PE (Clone GL1), CD80-APC (Clone 16-10A1), CD11c-FITC (Clone HL3.), MHC-II-FITC (Clone 39-10-8),...
for, 5′-AICDA-For, 5′-CACCCGTGTAGATGGATAG-3′; TACI-for, 5′-CCAGGGCATGTTGAG ATAGGATAG-3′ and Cyt-Rev (5′-AATGCCGACTGAGTTG-3′).

**Statistical Analysis**

All values were expressed as means ± SEM. Statistical differences between two groups were determined with the unpaired, two-tailed Student’s t-test. Data among four groups were analyzed using one-way ANOVA with Bonferroni’s post-hoc tests. All statistical analyses were performed using GraphPad Prism (Version 5.01). P < 0.05 were considered significant.

**RESULTS**

**Intranasal Chitosan-DNA Immunization Enhances VP1-Specific IgA Production and IgA CSR of B Cells in the Gut**

To investigate the effects of chitosan-DNA (pVP1) on gut IgA production, groups of BALB/c mice were intranasally immunized with 4 doses of DNA or chitosan-DNA comprising 50 µg DNA. VP1-specific IgA and IgG in the fecal extracts were measured by ELISA. VP1-specific IgA in feces of mice began to increase after two immunizations and reached a peak at wk8. Intranasal chitosan-DNA induced a significantly higher production of specific fecal IgA at wk8 than DNA vaccine did (P < 0.001, Figure 1A), whereas there was no difference in fecal IgG level between the two vaccine groups. It indicates that i.n. chitosan-DNA administration enhances VP1-specific IgA production in the intestine.

PPs usually constitute the IgA inductive site while LPs serve as mucosal effector sites. To clarify where chitosan-DNA-enhanced IgA+ B response occurs, we examined the IgA-producing B220+ plasmablasts in the MLNs, PPs and LPs of mice by FACS, using spleen as a systemic immunity compartment control. Although the highest proportion of plasmablasts was seen in PPs compared to other GALTs of mice, it is not different among various vaccine groups. IgA+ plasmablast percentage in MLNs of chitosan-DNA-immunized mice was approximately 3-fold higher than that of DNA-treated mice (Figure 1B). Enumeration of antigen-specific IgA+ plasmablasts in various GALTs of mice 2 weeks after final immunization by ELISPOT closely mirrored the results of flow cytometry. VP1-specific Ab-forming cells (AFCs) were weakly induced in the spleens and PPs and were not different among various vaccine groups; however, marked IgA responses (235 and 320 AFCs/10⁶ cells) were observed in the MLNs and LPs of chitosan-DNA-immunized mice that were significantly higher than those induced by DNA (105 and 265 AFCs/10⁶ cells) (Figure 1C).

Further, IgA+ plasma cells, defined as B220+IgA+IgM−CD138−IgD+, were predominantly found in LPs but rarely seen in the MLNs of mice; in both places chitosan-DNA induced a
higher generation of IgA⁺ plasma cells than DNA vaccine did (p < 0.05, **Figure 1D**). The above data suggest that IgA⁺ plasmablasts, which appear transiently after each vaccination, are predominantly induced in the MLNs, while lately IgA⁺ plasma cells are most efficiently recruited to the LPs of mice by intranasal chitosan-DNA.

Further, the B cell IgA germline transcripts including α-GT, ιμ-Cα, α-circle transcript (α-CT), and expression of AID gene which is a hallmark of ongoing IgA CSR were detected in MLN B cells. MLN B cells from chitosan-DNA-immunized mice showed a significant increase in the expression levels of Aicda, α-GT, ιμ-Cα, and α-CT compared to those from DNA-treated mice as determined by semi-quantitative RT-PCR assay. Consistently, Quantitative RT-PCR of the mRNA level of Aicda and α-GT generated similar results (**Figure 1E**), confirming the IgA CSR promoting capacity of chitosan-DNA vaccine.

Since mucosal B1 cells are also important source of IgA (35), wk8-immunized MLN B cells were phenotypically divided into B1a (B220⁺CD5lo), B1b (B220⁺CD5hi), and B2 (B220⁻CD5hi) cells according to B220 and CD5 expression. Bar graph represents the absolute number of B2-B cells. Histograms represent expression of mIgA by MLN B1 and B2-B cells after chitosan-DNA immunization. Data present mean ± SEM of three independent experiments (n = 6). **P < 0.01; *P < 0.05. **Figure 1F**. Taken together, i.n. chitosan-DNA immunization enhances the antigen-specific B2 response undergoing IgA CSR in the MLNs of mice.
Intranasal Chitosan-DNA Increases Tfh Differentiation Which Correlates With Promoted IgA Titer and Antigen-Specific Plasma Cell Frequency

Intestinal Ag-specific IgA is produced as a result of Tfh-B cell interactions in germinal centers (GC). Therefore, we detected the induction of Tfh response by intranasal chitosan-DNA. It was found that GC-resident CXCR5hi PD-1hi Tfh cells, whose function is to promote class switching and somatic hypermutation of naive B cells to produce high affinity IgA, were rarely found in LPs but predominantly present in MLNs. Tfh frequency was significantly increased by chitosan-DNA vaccination as compared with DNA or chitosan treatment (12.0 vs. 7.1 and 5.8% in CD4+ cells, Figure 2A). There was a strong correlation between Tfh frequency and IgA+plasma cell proportion (Figure 2B) as well as VP1-specific IgA titer (Figure 2C). It indicates that intranasal chitosan-DNA promotes GC Tfh differentiation leading to increased GC B reaction and enhanced IgA CSR.

Intranasal Chitosan-DNA Immunization Induces an Recruitment of CD103+DCs Into the MLNs

DCs have critical effects on IgA class switching of B cells (36). To track the DC response after chitosan-DNA immunization, FACS assay was plotted on lymphocytes in the MLNs, PPs, LPs, and spleens of mice. Notably, 24 h after i.n. chitosan-DNA immunization, a significant increase in CD11c+MHCII+ APCs frequency and numbers (Figure 3A) was only observed in the MLNs, but not in PPs or LPs of mice compared with DNA or chitosan immunization. Chitosan-DNA up-regulated CD80 and CD86 co-stimulatory molecules on DCs from various GALTs (Figure 3B).

MLN DCs can be roughly divided into 3 subsets: MHCIIhiCD11cint migratory DCs (mDCs), MHCIIintCD11chi resident DCs (rDCs) and MHCIIlowCD11cint plasmacytoid DCs (pDCs) (37). Flow cytometry analysis found that intranasal chitosan-DNA had no effect on MLN rDCs numbers, whereas induced a significant increase in proportions and numbers of MLN mDCs (Figure 3C). LP DCs comprise MHCII+CD11chi LP myeloid/migratory DC and MHCII+CD11cint LP macrophages (38). No significant differences in SI-LP DC numbers or subsets were observed although chitosan-DNA seemed to decrease proportions of LP-mDCs. 24 h after immunization, after first identifying intestinal mononuclear phagocytes/APCs as CD11c+MHCII+ cells among live leukocytes and then excluding CD64+macrophages, we found three discrete populations based on CD103 and CD11b expression: a majority population of CD103+CD11b+cDC2 and smaller numbers of CD103+CD11b−cDC1 and CD103−CD11b+ DCs. No differences were found in proportion and numbers of
CD64<sup>−</sup>CD103<sup>−</sup>CD11b<sup>+</sup> DCs in MLNs. However, a significant increase in frequencies and numbers of CD103<sup>+</sup>CD11b<sup>−</sup> cDC1 and CD103<sup>+</sup>CD11b<sup>+</sup> cDC2 (23.2 to 37.9%) within CD64-MHC II<sup>high</sup>CD11c<sup>+</sup> cells, \( p < 0.01 \) was induced by i.n. chitosan-DNA as compared to those by DNA vaccine (Figure 3D). In LP, there was a significant decrease in CD103<sup>+</sup>CD11b<sup>−</sup> cDC1 (39.4 to 28.2%) within CD64-MHC II<sup>high</sup>CD11c<sup>+</sup> cells, \( p < 0.01 \) population, while an increase in CD103<sup>+</sup>CD11b<sup>−</sup> DCs (\( p < 0.05 \)) and CD103<sup>+</sup>CD11b<sup>+</sup>cDC2 (\( p > 0.05 \)) population after chitosan-DNA vaccination. No differences was found in frequencies of CD11b<sup>−</sup> and CD11b<sup>+</sup> PP DC subsets (Figure 3E). Taken together, these data indicate that chitosan-DNA antigen sampling induces a migration of intestinal CD103<sup>+</sup>CD11b<sup>−</sup>mDCs from LP to the MLNs of mice 24 h after intranasal immunization.

**MLN CD103<sup>+</sup>DCs Induce IgA CSR in a Th-Dependent Way**

We next sought to determine whether CD103<sup>+</sup>DCs were responsible for chitosan-DNA-induced IgA CSR in the intestine. In an in vitro culture system, MHC II<sup>+</sup>CD11c<sup>+</sup>CD103<sup>+</sup>cells were flow sorted from MLNs of 24 h-immunized mice, co-cultured with MLN naïve CD19<sup>+</sup>IgM<sup>+</sup>B cells, and naïve CD4<sup>+</sup>Th0 cells at a ratio of 1/20/20 (DC/B/T) in the presence of chitosan-DNA for 7 days. VP1-specific IgA in the culture supernatants was quantified by ELISA. Only background levels of IgA production was observed from B cells if DCs or CD4<sup>+</sup>Th0 cells were absent. Significantly higher production of IgA was observed in the DC-T-B co-culture; and chitosan-DNA-primed CD103<sup>+</sup> DCs induced higher IgA production than DNA-primed CD103<sup>+</sup> DCs (Figure 4A). Flow cytometry analysis of IgA<sup>+</sup>B cells also confirmed higher IgA-secreting B cell frequency in the co-culture with chitosan-DNA-primed CD103<sup>+</sup> DCs than with DNA-primed DCs (Figure 4B). Further, in the DC-B-Th co-culture, increased expression of Aicda and α-GT transcript was detected after chitosan-DNA priming compared with DNA stimulation (Figure 4C).

Then, to see the involved cytokines contributing to the in vitro IgA CSR, we investigated the cytokine production by MLN...
DCs as the APCs co-cultured with naïve CD4+ Th0 and naïve IgM+ B cells in the presence of chitosan-DNA. Higher levels of IL-6, BAFF, and IL-17A but reduced levels of IL-12p40, IL-12p70, and IFNγ were produced in co-cultures with chitosan-DNA-primed MLN CD103+ DCs as APCs compared with DNA-primed DCs (Figure 4D). To see whether the increased IL-6, BAFF, and IL-17A are produced by DCs, we analyzed cytokine secretion from sorted CD103+ DCs following stimulation with DNA, chitosan-DNA and anti-CD40 mAb plus anti-IgM. It revealed that CD103+ DCs secreted significant levels of IL-6 and BAFF in response to chitosan-DNA, but low levels of IL-17A (Figure 4E) and IL-23 (data not shown). Since BAFF and APRIL are key cytokines for IgA CSR, we also detected the expression of membrane-bound APRIL (mAPRIL) on MLN CD103+ DCs 24 h after immunization and found unchanged mAPRIL expression (data not shown). These results indicate that intestinal CD103+ DCs induce IgA production after sampling chitosan-DNA antigen in a CD4+ T cell dependent way and that IL-6 and BAFF may be important for the DC-induced IgA secretion.

**MLN CD103+ DCs Induce IgA Upregulation via IL-6 and TACI Pathways**

Having established that upon chitosan-DNA immunization, MLN CD103+ DCs induced IgA CSR in a Th-dependent manner, we further examined the DC mechanisms involved. To clarify the role of BAFF, innate immune mediator that trigger IgA CSR in B cells by engaging the receptor TACI (39), in the induction of IgA, we first examined the expression of BAFFR, BCMA and TACI, candidate BAFF receptor, on sorted B cells from the wk8 chitosan-DNA-immunized mice after incubation with DNA and chitosan-DNA. No significant difference was observed between groups in mRNA levels of BCMA and BAFFR (Figures 5A, B), only TACI level was selectively increased by chitosan and chitosan-DNA incubation (Figure 5C). We then investigated TACI signaling contribution to IgA induction by using anti-TACI Ab. Blockade of TACI totally hampered the chitosan-DNA-enhanced IgA production in B-CD103+ DC-Th co-culture (Figure 5D). IL-6 has a critical role in inducing IgA within the gut (40). To examine whether IL-6 is responsible for the chitosan-DNA-induced IgA production described in Figure 4A,
blocking Ab specific for IL-6 was added to the DC-B-Th cell coculture system and it partially reduced IgA production in the coculture (Figure 5D), suggesting IL-6 signaling is involved in the CD103⁺DC-mediated IgA production. Taken together, CD103⁺DCs induce B-cell IgA production via BAFF-TACI and IL-6/IL-6R pathways in response to chitosan-DNA.

Chitosan-DNA-Primed CD103⁺DCs Promote Th17 Differentiation Which Is Required for the Vaccine-Upregulated IgA Response

In addition to releasing cytokines, intestinal CD103⁺DCs moderate gut immune responses in part by inducing regulatory or pro-inflammatory CD4⁺Th cells, which are required for TD IgA CSR (17, 19). In order to address the role of CD103⁺DCs to prime and stimulate naïve CD4⁺T cells in vitro, we co-cultured freshly isolated 24 h-chitosan-DNA–immunized MLN CD103⁺DCs with CFSE-labeled naïve CD4⁺CD62L⁺T cells in the presence of chitosan-DNA. Following 4-days co-culture, chitosan-pulsed CD103⁺DCs induced similar moderate levels of CFSE dilution as DNA-pulsed DCs, while chitosan-DNA-pulsed CD103⁺DCs were far more efficient at inducing T-cell division (60 vs. 34% and 20% CFSE dilution, Figure 6A).

To investigate the capacity of chitosan-DNA-primed CD103⁺DCs to induce the differentiation of Th17 or Treg cells in vitro, flow-sorted 24 h-immunized MLN CD103⁺DCs were co-cultured with CFSE-labeled naïve CD4⁺Th0 cells (1:20 ratio DC/T) for 4 days in the presence of DNA/chitosan-DNA and VP1 peptide, RORγt and Foxp3 expression by CD4⁺T cells were assessed. Compared to DNA priming, chitosan-DNA-pulsed CD103⁺DCs induced the highest frequency of IL-17A⁺RORγt⁺Th17 cells (Figures 6C,D, p < 0.001 and p < 0.05), whereas no difference in the Foxp3 expression was seen between DNA and chitosan-DNA-pulsed CD103⁺DCs (Figure 6B). Meanwhile, T cell activation was assessed by examining CD69 expression and CD62L downregulation after co-culture (Figure 6E). Compared to PBS and chitosan priming, DNA incubation moderately while chitosan-DNA significantly increased CD69 and down-regulated CD62L expression, indicating that in vitro antigen priming by CD103⁺DCs induced T cell activation.

In an attempt to understand why chitosan-DNA-treated CD103⁺DCs were more effective than DNA in priming Th17 cells, we examine the production of Th17-associated cytokines in co-culture supernatant. Chitosan-DNA-pulsed CD103⁺DCs induced higher production of IL-17A and IL-23 by CD4⁺Th cells (Figure 6F), suggesting they drive Th17 differentiation by secreting IL-6 and IL-23 in the MLN. Then we detected IL-17-producing T response in the intestine at wk8 post immunization. Intranasal chitosan-DNA induced elevated total IL-17⁺ T response in MLN than DNA vaccine. Specially, Th17 cell numbers in MLNs were significantly higher in chitosan-DNA-treated mice than in DNA-immunized mice (Figure 6G), indicating the preference of chitosan-DNA in inducing Th17 response in the intestine.

As chitosan-DNA favors to induce intestinal Th17 response in vivo and in vitro, we wish to test whether IL-17 is required for T cell-dependent IgA production achieved by intranasal chitosan-DNA. We i.n. immunized IL-17A⁻/⁻ and WT control mice with chitosan-DNA and analyzed fecal IgA response. VP1-specific IgA in feces was significantly reduced in IL-17A⁻/⁻ mice, in contrast to a strong IgA response in WT mice at wk8 post-immunization (Figure 6H). These results indicate that Th17 cells are required for the IgA switching in MLN after chitosan-DNA immunization.

Taken together, these data show that intranasal chitosan-DNA induces selective specific B cell IgA CSR in MLNs of mice which is dependent upon the recruitment of CD103⁺DCs into MLNs. CD103⁺DCs promotes IgA CSR via increasing the MLN Th1/Th17 differentiation and via producing BAFF and IL-6. Chitosan-DNA-increased MLN Th and Th17 responses are required for the production of antigen-specific IgA.

DISCUSSION

Here, we demonstrate a key role for intestinal CD103⁺DCs in the induction of T-dependent IgA response in the MLN following intranasal chitosan-DNA vaccination. Chitosan-DNA targets CD103⁺DCs, induces an accumulation of CD103⁺DCs in MLNs 24 h after immunization, and highly induces antigen-specific Th1 and Th17 responses which are indispensable for chitosan-DNA-enhanced IgA CSR. In the MLN, CD103⁺DC-derived IL-6 and BAFF are critical to activate IgA CSR of antigen-specific B cells via IL-6–IL-6R and BAFF-TACI signaling.

Given that most infectious pathogens including highly pathogenic influenza virus, M.tb, and HIV enter the host via mucosal surfaces, there is increasing interest in the establishment of protective mucosal immunity by mucosal vaccination in addition to systemic immunity (24, 41, 42). IgA production may lead to improved mucosal vaccines (8), and antigen-specific Th17 response is usually associated with enhanced neutralizing IgA exclusively after mucosal immunization (21). A switched antigen-specific CD4⁺T response from a systemic Th1 to a Th17 dominated mucosa-resident response (43) as well as local IgA response correlate with increased protection against mucosal pathogen infection (44). To solve the necessity to amplify the Th17/IgA responses to a wide array of antigens that are poorly immunogenic at the mucosal sites, cationic polysaccharide chitosan, has been widely utilized as carriers and adjuvants for mucosal vaccines. Meanwhile intranasal vaccination route is adopted since it helps to promote Th17-biased immunity to a variety of different TLR agonists (21, 45). Chitosan-formulated vaccines possess unique advantages like mucosal adhesion, opening the junctions to allow the paracellular transport of antigen, good tolerability, biocompatibility and excellent immune stimulation (46). More importantly, intranasal chitosan-adjuvanted DNA intends to induce an enhanced Th17-biased immune response compared with naked DNA vaccine (Figure 6F) which otherwise strongly increases Th1 immune responses in animals (47). In this regard, intranasal chitosan-DNA nanoparticles represents an effective system for promoting SlgA and Th17 response particularly in the gut, providing
enhanced protection against CVB3, an enterovirus (22–24). However, the cellular and molecular mechanism underlying intranasal chitosan-DNA-induced mucosal Th17 response and IgA switching in the gut remains unclear.

PPs are accepted as the principal inductive sites for TD IgA CSR (12, 13). However, MLNs represent alternate IgA inductive site and might be more required for IgA induction in the gastrointestinal tract (20, 48). In our study, to clarify the specific lymphoid tissues targeted by intranasal chitosan-DNA, we compared proportions and counts of migratory DCs (mDC) in various GALTs of mice 24 h after immunization. chitosan-DNA significantly induced an accumulation of CD11cintMHCIIhi mDCs, and most importantly, CD103+ mDCs in the MLN, but not in PP (Figures 3C,D). FACS or ELISPOT analysis of IgA+B220+ plasmablasts revealed a significant difference in the MLNs and LPs between chitosan-DNA- and DNA-immunized mice (Figures 1B,C). In addition to that, significantly promoted expression of essential hallmarks of active IgA CSR, AID, α-GT, ιμ-α and α-CT transcripts were observed in the MLN B cells of chitosan-DNA-treated mice (Figure 1E). Therefore, MLNs are the central target of nasal chitosan-DNA and the inductive sites for vaccine-enhanced IgA CSR.

In the intestinal mucosa, classical DC (cDC) comprise CD103+CD11b− (cDC1), CD103+CD11b+ (cDC2) and CD103−CD11b+ sub-populations. It has previously been shown that the cCD1 and cDC2 subsets require the transcription factors IRF8 and IRF4, respectively, during their development and differentiation. Each of these subsets plays key, non-redundant roles in controlling immune homeostasis in the intestinal mucosa (49). In commensal and food tolerance, LP-residing CD103+ DCs migrate to the MLNs where they drive the differentiation of gut-homing FoxP3+ Tregs by producing RA (50). Follicular IgA responses also require the migration of antigen-loaded CD103+ DCs to the interfollicular areas of PPs or MLNs to establish cognate interactions with precursors of Tfh cells, which are essential for the generation of plasma cells. We examined the kinetics of intestinal cDCs after vaccination. Intranasal chitosan-DNA drove a rapid accumulation of both CD103− and CD103+ cDC1 and cDC2 into the MLNs of mice 24 h after immunization. This MLN CD103+ DC accumulation coincided with a significant decrease in the frequencies and numbers of CD103−CD11b− LP-DCs (Figure 3D). Therefore, i.n. chitosan-DNA vaccination induces a migration of cDC1 from the LP to the MLNs of mice and an expansion of cDC2 in the MLNs, both of which may
promote Th17/Tfh differentiation and gut SIgA production. Such a LP-to-draining MLNs DC migration could be enhanced by oral, intranasal or intra-peritoneal administration of other adjuvants including TLR agonists (20, 51).

In the draining MLN, gut lumen antigen-sampled CD103+DCs play critical roles in the initiation of adaptive Th responses and SIgA production (15, 16, 52). CD103+CD11b+cDC2 play an important role in inducing

**FIGURE 6** | MLN CD103+DCs induce T cell proliferation and Th17 differentiation in vitro and in vivo which are required for IgA induction. (A) T cell division after 4-days culture of CD103+DCs and CD4+Th0. FACS-sorted CD103+DCs (1 × 10^4) from 24-h chitosan-DNA-immunized mice were co-cultured with CFSE-labeled naïve CD4+Th0 cells (5 × 10^4) in the presence of DNA or chitosan-DNA (5 ug/ml), and representative FACS plots of CFSE dilution were shown. (B–D) Representative dot plots show Foxp3 (B), RORγt (C) and IL-17A (D) induction in primed T cells at the start of culture and after 4 d of culture with CD103+DCs. T cells were stained for Foxp3, RORγt, IL-17A, and CD4 and analyzed by FACS. The graphs show percentages of Foxp3+, RORγt+ and IL-17A+ cells among CD4+ T cells in the presence of various antigen-pulsed CD103+DCs. Data from three independent experiments are summarized as mean ± SEM. **P < 0.01; *P < 0.05; ns, not significant. (E) T cell activation was assessed by evaluation expression of CD69 and downregulation of CD62L. Cells were gated as CD3+CD4+. Representative histograms show the MFI for CD69 and CD62L. Experiments were independently repeated three times (n = 3). (F) IL-17A and IL-23p19 production in the supernatant were detected by ELISA. Data presented as the mean ± SEM of three independent experiments. ***P < 0.001; **P < 0.01; *P < 0.05; ns, not significant. (G) MLN lymphocytes were isolated from wk8 chitosan-DNA-immunized mice and gated on CD45+CD3+T cells before IL-17A intracellular staining. IL-17A expression by CD4+Th and γδT cells was compared among various groups. Representative flow cytometry plots of IL-17+ cells and cumulative data quantifying of the number of Th17 or γδT17 cells were shown. Data are representative of three independent experiments and presented as the mean ± SEM (n = 6). ***P < 0.001; **P < 0.01; *P < 0.05; ns, not significant. (H) chitosan-DNA vaccine was i.n. administrated to WT and IL-17A KO mice biweekly for 4 times and the fecal SIgA was detected by ELISA at wk0 and wk8. Data are representative of three independent experiments and presented as the mean ± SEM (n = 6). ***P < 0.001; ns, not significant.
Foxp3⁺Treg and Th17 differentiation after sampling oral antigens and migrating to MLN (17, 19). DC2 are also important in inducing Th2 response (53). Whereas, CD103⁺CD11b⁺cDC1 have been reported to highly generate intestinal IFNγ+Th1 cells (54, 55) and also Tregs (56). CD103⁺DC-primed Tregs are associated with antigen-specific IgA induction (20). While recent evidence show that Th17 responses are required for optimal IgA induction (57–59). In consistency with previous report (19), by priming naïve CD4⁺Th0 cells with MLN CD103⁺DCs in the presence of chitosan-DNA and VP1 antigen, we found that chitosan-DNA-primed MLN CD103⁺DCs increased intestinal RORγt⁺IL-17A⁺Th17 cell differentiation and IL-17A/IL-23 production via secreting IL-6 (Figures 6A–E), but decreased DNA-triggered IFNγ production (Th1 response) most probably by reducing DC-secreting IL-12 (Figure 4D). In vivo, although we did not detect the change of IFNγ+Th1 response, the high production of IL-12 and IFNγ in the supernant of DC-B-Th co-culture in response to DNA and the nature of DNA vaccine all be considered an important factor to induce IgA response (40, 65, 66). TLR5 and TLR9 ligands (like CpG and DNA) could induce IL-6 production by CD103⁺CD11b⁺DCs (19, 67). While chitosan plus CpG promotes NLRP3-dependent Th17 cytokines production (28). In our study, BAFF (powerful IgA class switch molecule) and IL-6 (an IL-17-inducing cytokine and plasma cell differentiation modulator) were more profoundly secreted by CD103⁺DCs in response to chitosan-DNA than upon DNA directly or after CD4⁺Th0-B-DC co-culture (Figures 4D,E). As a result, IL-17A/IL-23 production in DC-CD4⁺Th0 co-culture was significantly enhanced which also favored IgA switching (Figures 4D, 6F). We further confirmed anti-IL-6 partially, while anti-TACI completely inhibited the IgA secretion in MLN B-Th0-DCs cell co-culture (Figure 5D). Taken together, BAFF-TACI and IL-6-IL-6R signaling considerably contribute to CD103⁺DC-mediated B cell IgA switching upon intranasal chitosan-DNA immunization. Other cytokine like thymic stromal lymphopoietin (TSLP) is thought involved in the activation of myeloid DC and induction of mucosal IgA responses upon mucosal immunization. Nasal CT-adjuvanted PsA vaccine upregulated TSLP and TSLPR expression in the mucosal DCs which promoted IgA-enhancing cytokines (APRIL, BAFF, and IL-6) expression. Whether TSLP-TSLPR signaling is involved in chitosan-adjuvanted DNA-induced IgA promotion needs further study (68).

Taken together, this is the first study to show that intranasal chitosan-DNA promotes IgA CSR of gut B cells via affecting CD103⁺DCs activation and promoting Th17/Tfh differentiation. Chitosan-DNA imprints MLN CD103⁺DCs to stimulate TD IgA switching through the action of two DC/B-cell axes, namely IL-6/IL-6R and BAFF-TACI pathways. Meanwhile, chitosan-DNA decreases CD4⁺Th1 but increases CD4⁺Th17 and Thh responses in MLN which are required for IgA production. The ability of chitosan-DNA to mobilize intestinal DC migration into the draining lymph node, to promote gut Th17/Tfh responses and to drive SlgA production may explain the exceptional adjuvant properties of this polysaccharide on mucosal immune response. These may together also offer a good basis for the development vaccines with high efficacy against mucosal viruses.

**AUTHOR CONTRIBUTIONS**

WX: conceived and supervised the project, wrote the manuscript. HZ, JY, and MW: performed the experiments. ML and QQ: participated discussion. All authors approved the final version of the paper.

**FUNDING**

This work was supported by NSFC grant (31270973, 31470869, 31670930, 31870903), China National Science and Technology Key Projects (2018ZX10731-001-006), the Jiangsu Provincial Innovative Research Team, and Program for Changjiang Scholars and Innovative Research Team in University (grant PCSIRTIRT1075).
REFERENCES

1. Macpherson A, Geuking M, McCoy K. Homeland security: IgA immunity at the frontiers of the body. Trends Immunol. (2012) 33:160–7. doi: 10.1016/j.ti.2012.02.002

2. Gutzeit C, Magri G, Cerutti A. Intestinal IgA production and its role in host-microbe interaction. ImmunoL. (2014) 260:76–85. doi: 10.1111/imm.12189

3. Yazdani R, Fatholahi M, Ganjalikhani-Hakemi M, Abolhasani H, Azizi G, Hamidi K et al. Role of apoptosis in common variable immunodeficiency and selective immunoglobulin A deficiency. Mol Immunol. (2016) 71:1–9. doi: 10.1016/j.molimm.2015.12.016

4. Smith A, Perelman M, Hinchcliffe M. Chitosan: a promising safe and immune-enhancing adjuvant for intranasal vaccines. Hum Vaccin Immunother. (2014) 10:797–807. doi: 10.4161/hv.27499

5. Kulkarni V, Ruprecht R. Mucosal IgA responses: damaged in established HIV infection-yet, effective weapon against HIV transmission. Front Immunol. (2014) 260:76–85. doi: 10.1111/imr.12189

6. Kulkarni V, Ruprecht R. Mucosal IgA responses: damaged in established HIV infection-yet, effective weapon against HIV transmission. Front Immunol. (2014) 260:76–85. doi: 10.1111/imr.12189

7. Kim S, Jang Y. The development of mucosal vaccines for both mucosal and systemic infection. Vaccine (2014) 32:2382–8. doi: 10.1016/j.vaccine.2013.12.043

8. Yoo Y, Xu W, Hu L, Jiang Z, Xiong S. Intranasal delivery of chitosan-DNA vaccine induces mucosal IgA and anti-CVBR3 protection. Vaccine (2004) 22:3603–12. doi: 10.1016/j.vaccine.2004.03.033

9. Watchmaker PB, Lahl K, Lee M, Baumjohann D, Morton J, Kim SJ et al. Comparative transcriptional and functional profiling defines conserved programs of intestinal DC differentiation in humans and mice. Nat Immunol. (2014) 15:98–108. doi: 10.1038/ni.2768

10. Persson EN, Uronen-Hansson H, Semmrich M, Rivottille A, Hagerbrand K, Marsal J et al. IRF4 transcription-factor-dependent CD103+ DCs induce Foxp3+ regulatory T cells through a TGF-beta and retinoic acid-dependent mechanism. J Exp Med. (2007) 204:1757–64. doi: 10.1084/jem.20070590

11. Sichien D, Lambrecht BN, Guilliams M, Scott CL. Development of conventional dendritic cells: from common bone marrow progenitors to multiple subsets in peripheral tissues. Mucosal Immunol. (2017) 10:831–44. doi: 10.1038/mi.2017.8

12. Coombs JL, Siddiqui KR, Aranchia-Carcamo CV, Hall J, Sun CM, Belkaid Y et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGFB-beta and retinoic acid-dependent mechanism. J Exp Med. (2007) 204:1757–64. doi: 10.1084/jem.20070590

13. Flores-Langarica A, Marshall JL, Hitchcock J, Cook C, Jobanputra J, Bobat S et al. Systemic flagellin immunization stimulates mucosal CD103+ dendritic cells and drives Foxp3+ regulatory T cell and IgA responses in the mesenteric lymph node. J Immunol. (2012) 189:5745–54. doi: 10.4049/jimmunol.1202283

14. Schultz O, Jaensson E, Persson EK, Liu X, Worbs T, Agace WW et al. Intestinal CD103+ dendritic cells promote SIgA to Chitosan-DNA vaccine. Front Immunol. (2016) 34:247–57. doi: 10.3389/fimmu.2015.12.016

15. Coombes JL, Siddiqui KR, Arancibia-Carcamo CV, Hall J, Sun CM, Belkaid Y et al. Intestinal CD103+ dendritic cells promote SIgA to Chitosan-DNA vaccine. Front Immunol. (2016) 34:247–57. doi: 10.3389/fimmu.2015.12.016

16. Sichien D, Lambrecht BN, Guilliams M, Scott CL. Development of conventional dendritic cells: from common bone marrow progenitors to multiple subsets in peripheral tissues. Mucosal Immunol. (2017) 10:831–44. doi: 10.1038/mi.2017.8

17. Watchmaker PB, Lahl K, Lee M, Baumjohann D, Morton J, Kim SJ et al. Comparative transcriptional and functional profiling defines conserved programs of intestinal DC differentiation in humans and mice. Nat Immunol. (2014) 15:98–108. doi: 10.1038/ni.2768

18. Persson EN, Uronen-Hansson H, Semmrich M, Rivottille A, Hagerbrand K, Marsal J et al. IRF4 transcription-factor-dependent CD103+ DCs induce Foxp3+ regulatory T cells through a TGF-beta and retinoic acid-dependent mechanism. J Exp Med. (2007) 204:1757–64. doi: 10.1084/jem.20070590

19. Flores-Langarica A, Marshall JL, Hitchcock J, Cook C, Jobanputra J, Bobat S et al. Systemic flagellin immunization stimulates mucosal CD103+ dendritic cells and drives Foxp3+ regulatory T cell and IgA responses in the mesenteric lymph node. J Immunol. (2012) 189:5745–54. doi: 10.4049/jimmunol.1202283

20. Gallorini S, Taccone M, Bonci A, Nardelli F, Casini D, Bonificio A et al. Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and IgG4 responses. Vaccine (2014) 32:2382–8. doi: 10.1016/j.vaccine.2013.12.043

21. Wu M, Zhao H, Li M, Yue Y, Xiong S, Xu W. Intranasal vaccination with mannosylated chitosan formulated DNA vaccine enables robust IgA and cellular response induction in the lungs of mice and improves protection against pulmonary mycobacterial challenge. Front Cell Infect Microbiol. (2017) 7:445. doi: 10.3389/fcimb.2017.00445

22. Park K, Mikulski Z, Seo GY, Andreyev AY, Marcovecchio P, Blatchley A et al. Comparative transcriptional and functional profiling defines conserved programs of intestinal DC differentiation in humans and mice. Mucosal Immunol. (2016) 9:336–51. doi: 10.1038/mi.2015.64

23. Yue Y, Xu W, Hu L, Jiang Z, Xiong S, Chen Y. Intranasal delivery of chitosan-DNA vaccine induces mucosal IgA and anti-CVBR3 protection. Vaccine (2004) 22:3603–12. doi: 10.1016/j.vaccine.2004.03.033

24. Watchmaker PB, Lahl K, Lee M, Baumjohann D, Morton J, Kim SJ et al. Comparative transcriptional and functional profiling defines conserved programs of intestinal DC differentiation in humans and mice. Nat Immunol. (2014) 15:98–108. doi: 10.1038/ni.2768

25. Persson EN, Uronen-Hansson H, Semmrich M, Rivottille A, Hagerbrand K, Marsal J et al. IRF4 transcription-factor-dependent CD103+ DCs induce Foxp3+ regulatory T cells through a TGF-beta and retinoic acid-dependent mechanism. J Exp Med. (2007) 204:1757–64. doi: 10.1084/jem.20070590

26. Flores-Langarica A, Marshall JL, Hitchcock J, Cook C, Jobanputra J, Bobat S et al. Systemic flagellin immunization stimulates mucosal CD103+ dendritic cells and drives Foxp3+ regulatory T cell and IgA responses in the mesenteric lymph node. J Immunol. (2012) 189:5745–54. doi: 10.4049/jimmunol.1202283

27. Park K, Mikulski Z, Seo GY, Andreyev AY, Marcovecchio P, Blatchley A et al. Comparative transcriptional and functional profiling defines conserved programs of intestinal DC differentiation in humans and mice. Mucosal Immunol. (2016) 9:336–51. doi: 10.1038/mi.2015.64
Zhao et al. CD103+ DCs Promote SIgA to Chitosan-DNA

39. Vincent FR, Saulep-Easton D, Figgett WA, Fairfax KA, Mackay F. The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev. (2013) 24:203–15. doi: 10.1016/j.cytogfr.2013.04.003
40. Sato A, Hashiguchi M, Toda E, Iwasaki A, Hachimura S, Kaminogawa S, CD11b+ Peyer’s patch dendritic cells secrete IL-6 and induce IgA secretion from naive B cells. J Immunol. (2003) 171:3684–90. doi: 10.4049/jimmunol.171.7.3684
41. Terauchi Y, Sano K, Ainai A, Saito S, Taga Y, Ogawa-Goto K, et al. IgA targeting human immunodeficiency virus-I envelope gp120 triggers antibody-dependent cellular cytotoxicity cross-clade and cooperates with gp41-specific IgG to increase cell lysis. Front Immunol. (2018) 9:244. doi: 10.3389/fimmu.2018.00244
42. Duchemin M, Khamassi M, Xu L, Tudor D, Bomsel M. IgA targeting B cell activation and mucosal IgA secretion from naive B cells. Immunother. (2018) 14:1351–61. doi: 10.1080/21645515.2018.1438791
43. Orr MT, Beebe EA, Hudson TE, Argilla D, Huang PW, Reese VA, et al. Classification of mucosal immune system: organized Peyer’s patches are not required for IgA responses in the small intestine and colon. Int Immunol. (2002) 14:822–9. doi: 10.1093/immunol/14.10.822
44. Singh B, Maharjan S, Cho KH, Cui L, Park IK, Choi YJ, et al. Chitosan-based particulate systems for the delivery of mucosal vaccines against infectious diseases. Int J Biol Macromol. (2018) 110:54–64. doi: 10.1016/j.ijbiomac.2017.10.101
45. Okuda K, Wada Y, Shimada M. Recent Developments in Preclinical DNA Vaccination. Vaccines (2014) 2:89–106. doi: 10.3390/vaccines20100089
46. Yamamoto M, Rennert P, McGhee JR, Kweon MN, Yamamoto S, Dohi T, et al. Alternate mucosal immune system: organized Peyer’s patches are not required for IgA responses in the gastrointestinal tract. J Immunol. (2000) 164:5184–91. doi: 10.4049/jimmunol.164.10.5184
47. Guiliams M, Duterre CA, Scott CL, McGovern N, Schien D, Chakarov S, et al. Unsupervised high-dimensional analysis aligns dendritic cells across tissues and species. Immunity (2016) 45:669–84. doi: 10.1016/j.immuni.2016.08.015
48. Scott CL, Aumenneur AM, Morawietz H, Finkes M, Murphy KM, et al. TSLP-responsive mucosal dendritic cells in the small intestine express TLR3, TLR7, and TLR9 and induce Th1 response and CTL activity. J Immunol. (2011) 187:733–47. doi: 10.4049/jimmunol.1002701
49. Lajemi MZ, Lecocq M, Weynand B, Bowen H, Gould HJ, Van Snick J, et al. Increased IgA production by B cells in COPD via lung epithelial interleukin-6 and TACI pathways. Eur Respir J. (2015) 45:980–93. doi: 10.1183/09031936.00063914
50. Fujimoto K, Karuppacamy T, Takemura N, Shimbogoshi M, Machida T, Haseda Y, et al. A new subset of CD103+CD16+ dendritic cells in the small intestine expresses TLR3, TLR7, and TLR9 and induces Th1 response and CTL activity. J Immunol. (2011) 187:8287–95. doi: 10.4049/jimmunol.1004036
51. Joo S, Fukuyama Y, Park EJ, Yuki Y, Kurashima Y, Ouchida R, et al. Distinct DC subsets regulate adaptive Th1 and 2 responses during Trichuris muris infection. Parasite Immunol. (2017) 39:5. doi: 10.1111/pim.12458
52. Shikawawa A, Kotake R, Takano T, Nakajima-Adachi H, Hachimura S, Mesenteric lymph node CD11b+CD103+ PD-1(High) dendritic cells highly induce regulatory T cells. Immunology (2017) 152:52–64. doi: 10.1111/imm.12747
53. Hirotta K, Turner JE, Villa M, Duarte JH, Demengeot J, Steinmetz OM, et al. Plasticity of Th17 cells in Peyer’s patches is responsible for the induction of T cell-dependent IgA responses. Nat Immunol. (2013) 14:372–9. doi: 10.1038/nm.2552
54. Demiri M, Muller-Luda K, Agace WW, Svensson-Frej M. Distinct DC subsets regulate adaptive Th1 and 2 responses during Trichuris muris infection. Parasite Immunol. (2017) 39:5. doi: 10.1111/pim.12458
55. Jaffe Z, Ferrini ME, Herritt LA, Roberts K. Cutting edge: lung mucosal Th17-mediated responses induce polymeric Ig receptor expression by the airway epithelium and elevate secretory IgA levels. J Immunol. (2009) 182:4507–11. doi: 10.4049/jimmunol.0900237
56. Dann SM, Manthey CF, Le C, Miyamoto Y, Gima L, Abraham A, et al. IL-17A promotes protective IgA responses and expression of other potential effectors against the lumen-dwelling enteric parasite Giardia. Exp Parasitol. (2015) 156:68–78. doi: 10.1016/j.exppara.2015.06.003
57. Litinsky MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, et al. DCs induce CD40-independent immunoglobulin class switching through BlyS and APRIL. Nat Immunol. (2002) 3:822–9. doi: 10.1038/nm829
58. Zhang Y, Li J, Zhang YM, Zhang XM, Tao J, Effect of TACI signaling on humoral immunity and autoimmune diseases. J Immunol Res. (2015) 2015:247426. doi: 10.1155/2015/247426
59. He B, Santamaria R, Xu W, Cols M, Chen K, Puga I, et al. The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat Immunol. (2010) 11:836–45. doi: 10.1038/nri.1914
60. Ozcan E, Rauter I, Garibyan L, Dillon SR, Ghez SA. Toll-like receptor 9, transmembrane activator and calcium-modulating cyclophilin ligand, and CD40 synergize in causing B-cell activation. J Allergy Clin Immunol. (2011) 128:601–9. doi: 10.1016/j.jaci.2011.04.052
61. Bekiaris V, Persson EK, Agace WW. Intestinal dendritic cells in the regulation of mucosal immunity. Immunol Rev. (2014) 260:86–101. doi: 10.1111/imr.12194
62. Denning TL, Norris BA, Medina-Contreras O, Manicassamy S, Geen D, Madan R, et al. Functional specializations of intestinal dendritic cell and macrophage subtypes that control Th17 and regulatory T cell responses are dependent on the T cell/APC ratio, source of mouse strain, and regional localization. J Immunol. (2011) 187:733–47. doi: 10.4049/jimmunol.1002701
63. Litinsky MB, Nardelli B, Hilbert DM, He B, Schaffer A, Casali P, et al. DCs induce CD40-independent immunoglobulin class switching through BlyS and APRIL. Nat Immunol. (2002) 3:822–9. doi: 10.1038/nm829

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Zhao, Yang, Qian, Wu, Li and Xu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.